Twogee Biotech Advances Industrial Enzyme Solutions for Circular Production

Founded in 2024 by Helge Jochens and Frank Wallrapp, Twogee Biotech focuses on developing customer-specific enzyme solutions and corresponding production strains, guiding them from laboratory research to full industrial production.

The company works closely with industrial partners to design tailored biotechnological processes that fit seamlessly into existing production environments. By emphasizing scalability and industrial relevance from the earliest development stages, Twogee ensures that its solutions are not only scientifically robust but also economically viable.

Twogee: From Laboratory Innovation to Industrial Application

Twogee Biotech enables industrial players to transform previously low-value biomass residues and by-products into sustainable second-generation raw materials. These residue-based inputs, as opposed to first-generation, food-based resources, are particularly suited for producing sugars used in bio-based and synthetic biology applications.

This transformation is driven by Twogee’s predictive development platform, which integrates enzyme screening, strain engineering, and fermentation processes in a coordinated, industry-oriented approach. As a result, development timelines are shortened and risks associated with scaling up are significantly reduced.

Commercialization, Partnerships, and Scalable Impact

The company was founded by Frank Wallrapp and Helge Jochens, each bringing more than a decade of combined industry experience in biotechnology. Supported by the BioM MAxL Incubator, Twogee Biotech is using its raised capital to accelerate both technological development and market entry. The company has already implemented initial minimum viable products and completed paid pilot projects with industrial partners, demonstrating the practical applicability of its approach.

Twogee’s business model includes licensing options that allow for local enzyme production directly at the customer’s site. This approach reduces operational costs and CO₂ emissions while supporting the creation of decentralized and circular value chains. According to CEO Frank Wallrapp, many industrial residues contain significant untapped value, and Twogee’s solutions are designed to unlock this potential with minimal integration effort and a clear economic perspective.

Following the completion of its seed financing round, which includes investors such as High-Tech Gründerfonds and Bayern Kapital alongside strategic partners like AgriFoodTech Venture Alliance and Heinz Entsorgung, Twogee Biotech is positioning itself as a key technological development partner for industrial companies. The funding supports the transformation of existing plants and material flows into circular, low-CO₂ value creation systems.

CTO and co-founder Helge Jochens notes that a substantial share of the financing will be invested in expanding the company’s laboratories at the IZB, equipping them with predictive bioreactor systems, and strengthening the team with experienced process and scale-up specialists. This focus ensures that Twogee’s developments remain reproducible and economically transferable to customers’ production scales.

__

(Featured image by Marek Piwnicki via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in VentureCapital. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.